MYL’s 40mg Copaxone ANDA has also been accepted by the FDA for review, according to a PR that just hit the wires: http://finance.yahoo.com/news/mylans-anda-three-times-per-152000383.html MYL claims it is eligible for shared first-to-file 180-day H-W exclusivity (implicitly acknowledging MNTA's PR).